Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 32,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo-Control Clear all
Completed Phase 2 Interventional Results available

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

NCT06334419
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Gaboxadol, Placebo
Drug
Lead sponsor
Craig Erickson
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips)

NCT03549130
View directory record Official record
Conditions
Congestion, Nasal
Interventions
Breathe Right Tan (small/medium) nasal strips, Placebo nasal strip
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

NCT00765128
View directory record Official record
Conditions
Renal Calculus, Kidney Stones
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 21, 2026, 3:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT01343628
View directory record Official record
Conditions
Alcohol-induced Cue-craving, Alcohol Sensitivity
Interventions
Placebo Comparator, Active Comparator: Atomoxetine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charlottesville/ Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Oral Androgens in Man-4: (Short Title: Oral T-4)

NCT00399165
View directory record Official record
Conditions
Contraception
Interventions
Testosterone Enanthate, Dutasteride, placebo sesame oil
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 21, 2026, 3:40 AM EDT
Suspended Phase 3 Interventional

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

NCT00353067
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
veliflapon (DG-031)
Drug
Lead sponsor
deCODE genetics
Industry
Eligibility
35 Years and older
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2006 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas

NCT00766467
View directory record Official record
Conditions
Malignant Glioma
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Eudocia Quant Lee, MD
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT03546907
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 75 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 21, 2026, 3:40 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636
View directory record Official record
Conditions
Change in Bone Mineral Density, Bone Loss
Interventions
drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
1,536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
27
States / cities
Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 4 Interventional Results available

Trial of Alvimopan in Major Spine Surgery

NCT02789111
View directory record Official record
Conditions
Constipation
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 4 Interventional Results available

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

NCT01236534
View directory record Official record
Conditions
Multiple Sclerosis, Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

NCT00880334
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer
Interventions
Docetaxel, vandetanib, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

NCT05145764
View directory record Official record
Conditions
Suvorexant, Placebo, Opioid Use Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Recruiting Phase 2 Interventional

RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring

NCT05292209
View directory record Official record
Conditions
Atrial Fibrillation Paroxysmal
Interventions
Riluzole 50 MG
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 1 Interventional

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism

NCT02366156
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, Low Dose Grape Blend, High Dose Grape Blend
Dietary Supplement
Lead sponsor
Access Business Group
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

NCT00629551
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
saredutant (SR48968), paroxetine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 21, 2026, 3:40 AM EDT
Not listed Phase 3 Interventional

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

NCT02847429
View directory record Official record
Conditions
GIST With D842V Mutated PDGFRA Gene
Interventions
Crenolanib, Placebo
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Santa Monica, California • Miami, Florida • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Sunnyvale, California • Englewood, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3832479 (LY-CoV016) in Healthy Participants

NCT04441931
View directory record Official record
Conditions
Healthy
Interventions
LY3832479, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Ceftriaxone in Subjects With ALS

NCT00349622
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
ceftriaxone, placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
50
States / cities
Phoenix, Arizona • Davis, California • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 3:40 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.

NCT01939951
View directory record Official record
Conditions
Mild to Moderate Persistent Asthma
Interventions
Activation Energy Serum
Dietary Supplement
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Early Phase 1 Interventional Results available

Pregabalin in the Treatment of Essential Tremor

NCT00646451
View directory record Official record
Conditions
Essential Tremor
Interventions
pregabalin (Lyrica), placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 21, 2026, 3:40 AM EDT